company background image
JAGX

Jaguar Health NasdaqCM:JAGX Stock Report

Last Price

US$0.17

Market Cap

US$20.0m

7D

-24.3%

1Y

-92.6%

Updated

24 Sep, 2022

Data

Company Financials +
JAGX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

JAGX Stock Overview

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea.

Jaguar Health Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jaguar Health
Historical stock prices
Current Share PriceUS$0.17
52 Week HighUS$2.66
52 Week LowUS$0.15
Beta1.65
1 Month Change-28.90%
3 Month Change-47.94%
1 Year Change-92.56%
3 Year Change-95.33%
5 Year Change-99.97%
Change since IPO-99.99%

Recent News & Updates

Aug 25

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Jaguar Health (NASDAQ:JAGX) announced Tuesday the sale of certain royalty rights to Utah-based Streeterville Capital for $4M consideration. The rights relate to future crofelemer and lechlemer revenue stream and some other up-front license fees, excluding any fees due to Jaguar from its crofelemer license for the European territory to its recently established Italian corporation - Napo Therapeutics - and will pay interest on the royalty payment amount at a rate of 10% annual until the same is paid in full. This transaction follows two royalty-based deals Jaguar executed in 2020, both of which also involved allocating proceeds to progress the company's ongoing Phase 3 pivotal OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea. "The commercial-stage pharmaceutical company is focused on concentrating its resources to two key development which includes "the completion of enrollment during the first half of 2023 for the OnTarget trial and the completion in 2022 of an investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome, supporting the potential for reimbursed expanded patient access through programs in Europe in 2023," commented Lisa Conte, Jaguar's president and CEO. Shares are up 3% in premarket on Thursday to trade at $0.24 vs. 52-week range of $0.22 to $3.75

Aug 19

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Jaguar Health (NASDAQ:JAGX) has been granted an additional 180-day grace period to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the pharmaceuticals company announced on Friday. The company must report a closing bid price of at least $1.00/share for a minimum of ten consecutive business days on or before Feb. 13, 2023 to show compliance. Speaking on the news, CEO Lisa Conte said, "Jaguar is focused on two late-stage clinical events in the next approximately 6 to 12 months that we expect to be transformational in terms of value creation and recognition for the company as we seek to regain compliance with the rule." An investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome (SBS) is anticipated to complete in 2022. The second key clinical activity is Jaguar's Phase 3 pivotal OnTarget trial of crofelemer for its core follow-on indication of prophylaxis of cancer therapy-related diarrhea. The company expects enrollment in this trial to complete in the first half of 2023.

Aug 09

Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea

Jaguar Health (NASDAQ:JAGX) said the United States Patent and Trademark Office had issued a new U.S. patent to its subsidiary, Napo Pharmaceuticals, for methods for treating diarrhea, as well as the pain, abdominal discomfort and other symptoms associated with diarrhea, in patients with an inhibitor of chloride-ion transport such as Napo's crofelemer drug product.  (JAGX) has risen 6.2%. The company's crofelemer drug product candidate is in ongoing Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.

Shareholder Returns

JAGXUS PharmaceuticalsUS Market
7D-24.3%-1.9%-5.2%
1Y-92.6%2.9%-23.0%

Return vs Industry: JAGX underperformed the US Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: JAGX underperformed the US Market which returned -23.1% over the past year.

Price Volatility

Is JAGX's price volatile compared to industry and market?
JAGX volatility
JAGX Average Weekly Movement10.0%
Pharmaceuticals Industry Average Movement11.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: JAGX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: JAGX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201352Lisa Contehttps://jaguar.health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Jaguar Health Fundamentals Summary

How do Jaguar Health's earnings and revenue compare to its market cap?
JAGX fundamental statistics
Market CapUS$19.97m
Earnings (TTM)-US$53.86m
Revenue (TTM)US$8.26m

2.4x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
JAGX income statement (TTM)
RevenueUS$8.26m
Cost of RevenueUS$2.00m
Gross ProfitUS$6.26m
Other ExpensesUS$60.12m
Earnings-US$53.86m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin75.81%
Net Profit Margin-652.41%
Debt/Equity Ratio1,135.7%

How did JAGX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is JAGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JAGX?

Other financial metrics that can be useful for relative valuation.

JAGX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.3x
Enterprise Value/EBITDA-1.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does JAGX's PS Ratio compare to its peers?

JAGX PS Ratio vs Peers
The above table shows the PS ratio for JAGX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.3x
JUVA.F Juva Life
3.6xn/aUS$19.6m
BFRI Biofrontera
0.8x50.1%US$21.7m
CLVR Clever Leaves Holdings
1.4x49.6%US$25.9m
GNRS Greenrose Holding
1xn/aUS$26.5m
JAGX Jaguar Health
2.4x46.2%US$20.0m

Price-To-Sales vs Peers: JAGX is expensive based on its Price-To-Sales Ratio (2.4x) compared to the peer average (1.3x).


Price to Earnings Ratio vs Industry

How does JAGX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: JAGX is good value based on its Price-To-Sales Ratio (2.4x) compared to the US Pharmaceuticals industry average (2.8x)


Price to Sales Ratio vs Fair Ratio

What is JAGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JAGX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ratio11.3x

Price-To-Sales vs Fair Ratio: JAGX is good value based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (11.3x).


Share Price vs Fair Value

What is the Fair Price of JAGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: JAGX ($0.17) is trading below our estimate of fair value ($36.34)

Significantly Below Fair Value: JAGX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Jaguar Health forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


50.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: JAGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: JAGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: JAGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: JAGX's revenue (46.2% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: JAGX's revenue (46.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if JAGX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Jaguar Health performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-19.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: JAGX is currently unprofitable.

Growing Profit Margin: JAGX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: JAGX is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.

Accelerating Growth: Unable to compare JAGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: JAGX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: JAGX has a negative Return on Equity (-1960.97%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Jaguar Health's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: JAGX's short term assets ($23.4M) exceed its short term liabilities ($22.9M).

Long Term Liabilities: JAGX's short term assets ($23.4M) do not cover its long term liabilities ($24.2M).


Debt to Equity History and Analysis

Debt Level: JAGX's net debt to equity ratio (808.8%) is considered high.

Reducing Debt: JAGX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: JAGX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: JAGX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.7% each year


Discover healthy companies

Dividend

What is Jaguar Health current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate JAGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate JAGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if JAGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if JAGX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as JAGX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Lisa Conte (63 yo)

9.25yrs

Tenure

US$1,891,227

Compensation

Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...


CEO Compensation Analysis

Compensation vs Market: Lisa's total compensation ($USD1.89M) is above average for companies of similar size in the US market ($USD780.01K).

Compensation vs Earnings: Lisa's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: JAGX's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: JAGX's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 160.1%.


Top Shareholders

Top 25 shareholders own 25.63% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.59%
Streeterville Management LLC
11,500,000$1.9m0%no data
3.84%
Oasis Capital, LLC
4,604,484$767.1k0%11.5%
3.64%
Joshua Mailman Foundation, Endowment Arm
4,366,665$727.5k0%no data
3.41%
Joshua Mailman
4,088,758$681.2k0%no data
1.85%
The Vanguard Group, Inc.
2,212,248$368.6k105.69%no data
0.99%
Renaissance Technologies LLC
1,186,744$197.7k-22.08%no data
0.54%
BlackRock, Inc.
652,934$108.8k-14.73%no data
0.44%
Millennium Management LLC
533,153$88.8k152.25%no data
0.34%
Geode Capital Management, LLC
411,365$68.5k8.01%no data
0.14%
BNY Mellon Asset Management
168,788$28.1k-0.57%no data
0.13%
Ejm 2012 Trust
158,715$26.4k0%no data
0.13%
Virtu Financial LLC, Asset Management Arm
154,275$25.7k-32.71%no data
0.12%
State Street Global Advisors, Inc.
140,338$23.4k6.45%no data
0.097%
Group One Trading LP, Asset Management Arm
115,717$19.3k20.03%no data
0.062%
Northern Trust Global Investments
74,699$12.4k0%no data
0.062%
James Bochnowski
73,765$12.3k0%no data
0.061%
Morgan Stanley, Investment Banking and Brokerage Investments
72,592$12.1k-58.06%no data
0.041%
JPMorgan Chase & Co, Brokerage and Securities Investments
49,454$8.2k137.43%no data
0.032%
UBS Asset Management
38,740$6.5k0%no data
0.024%
BB&T Trust
29,341$4.9k0%no data
0.024%
Merit Financial Advisors Llc
29,000$4.8k0%no data
0.015%
LPL Financial Corporation, Asset Management Arm
17,968$3.0k0%no data
0.014%
Jonathan Siegel
16,558$2.8k0%no data
0.01%
Carol Lizak
12,481$2.1k56.64%no data
0.01%
John Micek
12,133$2.0k0%no data

Company Information

Jaguar Health, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Jaguar Health, Inc.
  • Ticker: JAGX
  • Exchange: NasdaqCM
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$19.969m
  • Shares outstanding: 119.86m
  • Website: https://jaguar.health

Number of Employees


Location

  • Jaguar Health, Inc.
  • 200 Pine Street
  • Suite 400
  • San Francisco
  • California
  • 94104
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
JAGXNasdaqCM (Nasdaq Capital Market)YesVoting Common StockUSUSDAug 2017
1JADB (Deutsche Boerse AG)YesVoting Common StockDEEURAug 2017

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.